Universität zu Köln

Paitazoglou, Christina, Bergmann, Martin W., Ozdemir, Ramazan, Pfister, Roman, Bartunek, Jozef, Kilic, Teoman, Lauten, Alexander, Schmeisser, Alexander, Zoghi, Mehdi ORCID: 0000-0002-8156-2675, Anker, Stefan D., Sievert, Horst and Mahfoud, Felix (2021). One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur. J. Heart Fail., 23 (5). S. 800 - 811. HOBOKEN: WILEY. ISSN 1879-0844

Full text not available from this repository.

Abstract

Aims Attenuating exercise-induced elevated left atrial pressure with an atrial shunt device is under clinical investigation for treatment of symptomatic heart failure (HF). Methods and results PRELIEVE was a prospective, non-randomised, multicentre, first-in-man study in symptomatic HF patients with reduced (HFrEF) or preserved (HFpEF) ejection fraction and pulmonary capillary wedge pressure (PCWP) >= 15 mmHg at rest or >= 25 mmHg during exercise. Here, we provide follow-up data up to 1 year after implantation of the Atrial Flow Regulator (AFR) device. The AFR was successfully implanted in 53 patients (HFrEF n = 24 and HFpEF n = 29). Two patients were not enrolled due to an unsuccessful transseptal puncture. There was one device embolisation into the left atrium, which required surgical removal. One patient experienced a serious procedure-related adverse event (post-procedural bleeding and syncope). All patients with sufficient echocardiography readout confirmed device patency with left-right shunt both at 3 (n = 47/51, 92%) and 12 (n = 45/49, 92%) months. At 3 months, rest PCWP decreased by 5 (-12, 0) mmHg (P = 0.0003, median Q1, Q3). No patient developed a stroke, worsening of right heart function or significant increase of pulmonary artery pressure. Six (6/53, 11%) patients were hospitalised for worsening of HF and three (3/53, 6%) patients died. We observed improvements in New York Heart Association functional class, 6-min walking distance and quality of life (Kansas City Cardiomyopathy Questionnaire) in certain patients. Conclusions Implantation of the AFR device in HF patients was feasible. No shunt occlusion, stroke or new right HF was observed during the 1-year follow-up, with clinical improvements in certain patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Paitazoglou, Christina UNSPECIFIED UNSPECIFIED UNSPECIFIED Bergmann, Martin W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ozdemir, Ramazan UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfister, Roman UNSPECIFIED UNSPECIFIED UNSPECIFIED Bartunek, Jozef UNSPECIFIED UNSPECIFIED UNSPECIFIED Kilic, Teoman UNSPECIFIED UNSPECIFIED UNSPECIFIED Lauten, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmeisser, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Zoghi, Mehdi UNSPECIFIED orcid.org/0000-0002-8156-2675 UNSPECIFIED Anker, Stefan D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sievert, Horst UNSPECIFIED UNSPECIFIED UNSPECIFIED Mahfoud, Felix UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-600647
DOI:	10.1002/ejhf.2119
Journal or Publication Title:	Eur. J. Heart Fail.
Volume:	23
Number:	5
Page Range:	S. 800 - 811
Date:	2021
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1879-0844
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Cardiac & Cardiovascular Systems Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/60064